<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T14:53:54Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/71464" metadataPrefix="mods">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/71464</identifier><datestamp>2024-12-11T10:53:05Z</datestamp><setSpec>com_10324_1138</setSpec><setSpec>com_10324_931</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_1226</setSpec></header><metadata><mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Di Pierdomenico, Johnny</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Gallego-Ortega, Alejandro</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Norte-Muñoz, María</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Vidal-Villegas, Beatriz</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Bravo, Isaac</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Boluda-Ruiz, María</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Bernal-Garro, Jose Manuel</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Fernández Bueno, Iván</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Pastor Jimeno, José Carlos</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Villegas-Pérez, María Paz</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Avilés-Trigueros, Marcelino</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>de los Ríos, Cristobal</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Vidal Sanz, Manuel Antón</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2024-11-14T12:14:36Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2024-11-14T12:14:36Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2024</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Frontiers in Neuroanatomy 2024;18</mods:identifier>
<mods:identifier type="uri">https://uvadoc.uva.es/handle/10324/71464</mods:identifier>
<mods:identifier type="doi">10.3389/fnana.2024.1335176</mods:identifier>
<mods:identifier type="publicationtitle">Frontiers in Neuroanatomy</mods:identifier>
<mods:identifier type="publicationvolume">18</mods:identifier>
<mods:identifier type="essn">1662-5129</mods:identifier>
<mods:abstract>Purpose: The aim of this study was to investigate, the neuroprotective effects of&#xd;
a new Gramine derivative named: ITH12657, in a model of retinal excitotoxicity&#xd;
induced by intravitreal injection of NMDA.&#xd;
Methods: Adult Sprague Dawley rats received an intravitreal injection of 100 mM&#xd;
NMDA in their left eye and were treated daily with subcutaneous injections of&#xd;
ITH12657 or vehicle. The best dose–response, therapeutic window study, and&#xd;
optimal treatment duration of ITH12657 were studied. Based on the best survival of&#xd;
Brn3a + RGCs obtained from the above-mentioned studies, the protective effects of&#xd;
ITH12657 were studied in vivo (retinal thickness and full-field Electroretinography),&#xd;
and ex vivo by quantifying the surviving population of Brn3a + RGCs, αRGCs and&#xd;
their subtypes α-ONsRGCs, α-ONtRGCs, and α-OFFRGCs.&#xd;
Results: Administration of 10 mg/kg ITH12657, starting 12 h before NMDA&#xd;
injection and dispensed for 3 days, resulted in the best significant protection&#xd;
of Brn3a + RGCs against NMDA-induced excitotoxicity. In vivo, ITH12657-&#xd;
treated rats showed significant preservation of retinal thickness and functional&#xd;
protection against NMDA-induced retinal excitotoxicity. Ex vivo results showed&#xd;
that ITH12657 afforded a significant protection against NMDA-induced&#xd;
excitotoxicity for the populations of Brn3a + RGC, αRGC, and αONs-RGC, but&#xd;
not for the population of αOFF-RGC, while the population of α-ONtRGC was&#xd;
fully resistant to NMDA-induced excitotoxicity.&#xd;
Conclusion: Subcutaneous administration of ITH12657 at 10 mg/kg, initiated&#xd;
12 h before NMDA-induced retinal injury and continued for 3 days, resulted in the&#xd;
best protection of Brn3a + RGCs, αRGC, and αONs-RGC against excitotoxicity-&#xd;
induced RGC death. The population of αOFF-RGCs was extremely sensitive&#xd;
while α-ONtRGCs were fully resistant to NMDA-induced excitotoxicity.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by-nc-nd/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">Attribution-NonCommercial-NoDerivatives 4.0 Internacional</mods:accessCondition>
<mods:titleInfo>
<mods:title>Evaluation of the neuroprotective efficacy of the gramine derivative ITH12657 against NMDA-induced excitotoxicity in the rat retina</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods></metadata></record></GetRecord></OAI-PMH>